Moreover, low levels of ALKBH5 predicted poor clinical outcome in PDAC and multiple other cancers including Phenochromocytoma and Paraganglioma, Stomach adenocarcinoma, and Uterine corpus endometrial carcinoma (Fig. 1h and Additional file 2: Figure S2b-d). Here, ALKBH5 is linked to cancer.